You BETer be aware – learnings from a negative Phase 1 study

por Postel-Vinay, Sophie, Ocker, Matthias
Publicado 2019

La communication sur le SRAS : un outil essentiel de santé publique

por Postel-Vinay, N., Chemardin, J.
Publicado 2004

Immunotherapy for SMARCB1-Deficient Sarcomas: Current Evidence and Future Developments

por Ngo, Carine, Postel-Vinay, Sophie
Publicado 2022

How Much Can We Bet on Activity of BET Inhibitors Beyond NUT–Midline Carcinoma?

por Martin-Romano, Patricia, Baldini, Capucine, Postel-Vinay, Sophie
Publicado 2019

Coronavirus disease (COVID-19) outbreak and phase 1 trials: should we consider a specific patient management?

por Postel-Vinay, Sophie, Massard, Christophe, Soria, Jean-Charles
Publicado 2020

The Challenges for Labour Market Policy during the COVID‐19 Pandemic

por Costa Dias, Monica, Joyce, Robert, Postel‐Vinay, Fabien, Xu, Xiaowei
Publicado 2020

Management of arterial hypertension: home blood pressure measurement is a cornerstone for telemonitoring and self-management

por Postel-Vinay, Nicolas, Bobrie, Guillaume, Asmar, Roland, Stephan, Dominique, Amar, Laurence
Publicado 2023

Role of Prolactin and Growth Hormone on Thymus Physiology

por De Mello-Coelho, Valéria, Savino, Wilson, Postel-Vinay, Marie-Catherine, Dardenne, Mireille
Publicado 1998

Beyond DNA repair: the novel immunological potential of PARP inhibitors

por Chabanon, Roman M., Soria, Jean-Charles, Lord, Christopher J., Postel-Vinay, Sophie
Publicado 2019

Physical activity in patients with type 2 diabetes and hypertension – insights into motivations and barriers from the MOBILE study

por Duclos, Martine, Dejager, Sylvie, Postel-Vinay, Nicolas, di Nicola, Sylvie, Quéré, Stéphane, Fiquet, Béatrice
Publicado 2015

Home Blood Pressure Measurement and Self-Interpretation of Blood Pressure Readings During Pregnancy: Hy-Result e-Health Prospective Study

por Postel-Vinay, Nicolas, Shao, Jiali-Delphine, Pinton, Anne, Servais, Aude, Gebara, Nicole, Amar, Laurence
Publicado 2022

Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?

por Postel-Vinay, S, Arkenau, H-T, Olmos, D, Ang, J, Barriuso, J, Ashley, S, Banerji, U, De-Bono, J, Judson, I, Kaye, S
Publicado 2009

Impact of COVID-19 Pandemic on Cancer Research

por Zon, Leonard, Gomes, Ana P., Cance, William G., Ribas, Antoni, Tuveson, David, Postel-Vinay, Sophie, Massard, Christophe, Barlési, Fabrice
Publicado 2020

First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours

por Ameratunga, Malaka, Braña, Irene, Bono, Petri, Postel-Vinay, Sophie, Plummer, Ruth, Aspegren, John, Korjamo, Timo, Snapir, Amir, de Bono, Johann S
Publicado 2020

A Case-Control Study Brings to Light the Causes of Screen Failures in Phase 1 Cancer Clinical Trials

por Kempf, Emmanuelle, Lemoine, Nathalie, Tergemina-Clain, Gabrielle, Turpin, Anthony, Postel-Vinay, Sophie, Lanoy, Emilie, Soria, Jean-Charles, Massard, Christophe, Hollebecque, Antoine
Publicado 2016

Patient-reported tolerability of adverse events in phase 1 trials

por Henon, Clémence, Lissa, Delphine, Paoletti, Xavier, Thibault, Constance, Le Tourneau, Christophe, Lanoy, Emilie, Hollebecque, Antoine, Massard, Christophe, Soria, Jean-Charles, Postel-Vinay, Sophie
Publicado 2017

Time to progression ratio in cancer patients enrolled in early phase clinical trials: time for new guidelines?

por Watson, Sarah, Menis, Jessica, Baldini, Capucine, Martin-Romano, Patricia, Michot, Jean-Marie, Hollebecque, Antoine, Armand, Jean-Pierre, Massard, Christophe, Soria, Jean-Charles, Postel-Vinay, Sophie, Paoletti, Xavier
Publicado 2018

Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types

por Martin‐Romano, Patricia, Castanon, Eduardo, Ammari, Samy, Champiat, Stéphane, Hollebecque, Antoine, Postel‐Vinay, Sophie, Baldini, Capucine, Varga, Andrea, Michot, Jean Marie, Vuagnat, Perrine, Marabelle, Aurélien, Soria, Jean‐Charles, Ferté, Charles, Massard, Christophe
Publicado 2020

BAP1 complex promotes transcription by opposing PRC1-mediated H2A ubiquitylation

por Campagne, Antoine, Lee, Ming-Kang, Zielinski, Dina, Michaud, Audrey, Le Corre, Stéphanie, Dingli, Florent, Chen, Hong, Shahidian, Lara Z., Vassilev, Ivaylo, Servant, Nicolas, Loew, Damarys, Pasmant, Eric, Postel-Vinay, Sophie, Wassef, Michel, Margueron, Raphaël
Publicado 2019

Lorlatinib in ALK- or ROS1-rearranged non-small cell lung cancer: an international, multicenter, open-label phase 1 trial

por Shaw, Alice T., Felip, Enriqueta, Bauer, Todd M., Besse, Benjamin, Navarro, Alejandro, Postel-Vinay, Sophie, Gainor, Justin F., Johnson, Melissa, Dietrich, Jorg, James, Leonard P., Clancy, Jill S., Chen, Joseph, Martini, Jean-François, Abbattista, Antonello, Solomon, Benjamin J.
Publicado 2017